Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events.

about

Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events.

Item

http://www.wikidata.org/entity/Q38688827

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Aspirin dosing frequency in th ...... tion of cardiovascular events.

@en

type

Item

label

Aspirin dosing frequency in th ...... tion of cardiovascular events.

@en

prefLabel

Aspirin dosing frequency in th ...... tion of cardiovascular events.

@en

P1476

Aspirin dosing frequency in th ...... tion of cardiovascular events.

@en

P2093

Joonseok Kim

http://www.w3.org/2001/XMLSchema#string

Richard C Becker

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association

Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE)

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Cyclooxygenase-1 haplotype modulates platelet response to aspirin

P2888

s11239-015-1307-2

P304

493-504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11239-015-1307-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

289535846

http://www.w3.org/2001/XMLSchema#string

P698

26739313

http://www.w3.org/2001/XMLSchema#string